Markus Renschler, MD
Senior Vice President, Global Head, Hematology & Oncology Medical Affairs at Celgene
Dr. Markus Renschler is a medical oncologist with 25 years’ experience in cancer research from basic laboratory research to drug approval. He has been in the pharmaceutical industry in Clinical R&D and Medical Affairs for more than 20 years, with successful global registrations in breast cancer, NSCLC and pancreatic cancer. Dr. Renschler has been at Celgene for the past 8 years and currently is the Senior Vice President, Global Head of Hematology & Oncology Medical Affairs. He is responsible for post-marketing medical strategy and all non-registrational clinical research world-wide for all compounds. He joined Celgene in 2008 and has had leading roles in Clinical R&D, Project Leadership and Business Development. As Vice President, Clinical R&D, Dr. Renschler led global clinical trial programs in lung and pancreatic cancer and melanoma. Prior to Celgene, Dr. Renschler worked in industry for 12 years at Pharmion and Pharmacyclics, responsible for the clinical development of drugs for several solid tumors and hematologic malignancies. Dr. Renschler was a post-doctoral fellow with Dr. Ronald Levy at Stanford University, working on patient-specific vaccines and antibody treatments for Non-Hodgkin lymphoma. He is a board certified medical oncologist with an MD from Stanford University and BA from Princeton University. Dr. Renschler was an Adjunct Clinical Associate Professor of Medicine (Oncology) at Stanford University until August 2015, where he was teaching and treating patients in the lymphoma program.